Mirjam Fässler
Kantonsspital St. Gallen(CH)Institute of Immunology(HR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer(2019)383 cited
- → Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors(2018)178 cited
- → BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors(2019)98 cited
- → Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients(2019)83 cited
- → Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment(2019)30 cited
- → Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms(2019)26 cited
- → Successful treatment of refractory folliculitis decalvans with apremilast(2020)22 cited
- → Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab(2020)17 cited
- → Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment(2018)2 cited
- → LB1513 Autoantibodies against collagen XVII (BP180) favor the development of cutaneous toxicity during checkpoint inhibitor therapy(2018)